-Caveat Lector- <A HREF="http://www.ctrl.org/"> </A> -Cui Bono?- Regarding Darpa Unconventional Pathogen Countermeasure program: Dr. Baker's research is now being tested in atmospheric release, according to sources. Key researcher:James R. Baker Jr., M.D., <[EMAIL PROTECTED]> Key words of current research interest: - gene transfer - autoimmunity - biologic weapons Description of research: Autoimmune endocrine disease. Gene transfer using a synthetic polymer. Development of pathogen countermeasures. Summary of current research: Dr. Baker has several research projects in progress. One is in the area of autoimmune endocrine disease and he has helped define the basis of the autoimmune response to thyroid autoantigens. In particular, his recent work has focused on epitope mapping of thyroid peroxidase, a major autoantigen in autoimmune thyroid disease. His laboratory has used molecular biologic techniques to identify the specific epitopes recognized in TPO and shown that the recogition of this autoantigen is heterogeneous in different individuals. He is currently exploring the genetic basis of this recognition. Furthermore, Dr. Baker is investigating the regulation of programmed cell death pathways in the thyroid and how they may prevent the development of thyroiditis by protecting thyroid cells from immune mediated apoptosis. For more information on Thyroid Autoimmunity and Cancer Another major interest of Dr. Baker focuses on preventing pathogens from entering the human body, which is a major goal in the development of counter measures to Biological Warfare. This research project seeks to develop a composite material that will serve as a pathogen avoidance barrier and post-exposure therapeutic agent to be applied in a topical manner to the skin and mucous membranes. The composite is modelled after the immune system in that it involves redundant, non-specific and specific forms of pathogen defense and inactivation. For more information on Pathogen Counter Measures Dr. Baker has a special interest in dendritic polymers and their application to medical and biological science. He has co-developed a new vector system for gene transfer using synthetic polymers. These studies have produced striking results and have the potential to change the basis of gene transfer therapy. Dendrimers are nanometer-sized water-soluble polymers that can be conjugated to peptides or carbohydrates to act as decoy molecules to inhibit the binding of toxins and viruses to cells. They can also complex and stabilize genetic material for prolonged periods of time. Dr. Baker's group has extensive experience with dendrimers and has demonstrated that dendrimers can transfect epithelial cells. For more information on Dendritic Polymers in Biology The site Dan listed http://www.darpa.mil/DSO/rd/UPC/index.html returns 404 error, not found. Has anyone visited this site recently, and if so, have you saved information from the site, or can you retrieve it from your cache? (just try connecting to the site). Hotbot lists this, site which returns 404 not found. Unconventional Pathogen Countermeasures 1/8/00 http://www.arpa.mil/dso/rd/upc/0011_Lg.html This site http://www.state.sc.us/epd/emtools/hazard4.htm , State of South Carolina has a link to: http://www.bwd.org/upc/index.html which briefly flashes a message about "biowar" and then forwards to the http://www.darpa.mil/DSO/rd/UPC/ site, which is 404'd. Same link is on the State of Florida's "Web of Justice" Domestic Preparedness and Weapons of Mass Destruction Links http://www.co.pinellas.fl.us/bcc/juscoord/eweapon.htm I believe I smell deepening coverup. Further reference to the Darpa Unconventional Pathogen Countermeasure program: The University of Michigan News and Information Services News Release 412 Maynard Ann Arbor, Michigan 48109-1399 September 23, 1998 (25) New agent kills influenza virus, prevents infection in mice FOR RELEASE AT 11:30 a.m., PDT, SATURDAY, SEPTEMBER 26, 1998. EDITORS: An announcement describing BCTP and the material's anti-microbial properties is being released simultaneously by Novavax, Inc. http://www.novavax.com/ SAN DIEGO---University of Michigan scientists have tested a new anti-microbial agent and found it to be a quick and efficient killer of influenza A virus in cell cultures and in the nasal passages of laboratory mice. "These are preliminary, small-scale studies, but the results indicate this material called BCTP shows promise as a new weapon against the influenza A virus," says James R. Baker Jr., M.D., <[EMAIL PROTECTED]> professor of internal medicine and director http://www.med.umich.edu/intmed/allergy/biobaker.htm Center for Biologic Nanotechnology http://www.med.umich.edu/intmed/allergy/nano.htm in the U-M Medical School. "Its main advantages are its rapid killing action, lack of specificity and the fact that it is non-toxic to skin and mucous membranes." A milky-white emulsion of tiny lipid droplets suspended in solvent, BCTP was developed by D. Craig Wright, M.D., chief research scientist at Novavax, Inc., and president of Novavax Biologics Division. Novavax is a bio-pharmaceutical company located in Columbia, Md. According to Wright, the material is made of water, soybean oil, Triton X 100 detergent and the solvent tri-n-butyl phosphate. In presentations at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 26, U-M research associates Andrzej Myc and Jon D. Reuter presented results of preliminary studies evaluating BCTP's effect on influenza A. Both research studies were funded by the Defense Advanced Research Projects Agency (DARPA) and directed by Baker. Myc's study used Madin Darby Canine Kidney cells, used by researchers to evaluate the toxic effects of viruses. Myc incubated MDCK cells with influenza A virus and five different formulations of Novavax lipid structures. Using two different assay techniques, Myc then measured the number of cells infected with the virus. While all five formulations slowed the spread of the virus, BCTP was the most potent, reducing viral antigen levels by 99.6 percent. In Reuter's study, different liquids were inserted into the nasal passages of four groups of laboratory mice. Control mice in Group 1 were given ordinary saltwater. Group 2 received BCTP alone. Group 3 received live influenza A virus and Group 4 was given a mixture of influenza A and BCTP. Groups 1, 2 and 4 stayed healthy, while all the mice in Group 3 developed severe pneumonia and two out of three mice died before the conclusion of the study. "We learned several important things from these preliminary studies. The first is that BCTP is a highly effective killing agent for the influenza virus both at the cellular level and in living animals. Equally important is that BCTP had no toxic effects on nasal or lung membranes," Baker says. "We've shown that if we treat the virus with BCTP as it enters the nasal passages, we can prevent infection in mice. The next step is to see whether we can administer BCTP and the virus separately and still prevent infection. And the final step, of course, is to see whether it works as well in people as it does in mice." While influenza vaccines are relatively effective at preventing the flu, Baker says there is a need for alternate preventive agents. "Influenza vaccines are expensive, they only are effective against a few viral strains each year and it takes time for immunity to develop. BCTP appears to inactivate the virus on contact." The research is funded by DARPA's Unconventional Pathogen Countermeasures Program. http://www.darpa.mil/DSO/rd/UPC/index.html (404, not found) The U-M and Novavax have filed a patent application covering BCTP's use as a decontamination agent for various anti-microbial applications. Baker is a member of the Novavax scientific advisory board, but has no significant financial interest in the company. Contact: Sally Pobojewski Phone: (734) 647-1844 E-mail: [EMAIL PROTECTED] ============= REDWOOD CITY, Calif. – February 2, 1999 –Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that it has been notified by the Defense Advanced Research Projects Agency (DARPA) that its three-year research grant will be funded for a second year. Funding of $4.8 million for the second year is an increase of more than 25% over the $3.8 million received in 1998. Genelabs is conducting drug discovery research on behalf of the Unconventional Pathogen Countermeasures Program sponsored by DARPA, applying Genelabs' patented technologies to the discovery of drugs that can be used as countermeasures to agents of biological warfare. Dave Hartley http://www.Asheville-Computer.com/dave -----Original Message----- From: Mike Castle [mailto:[EMAIL PROTECTED]] Sent: Monday, January 24, 2000 12:50 PM To: Dave Subject: Re: FW: Chemtrails Flu / NSA Dave, I got your FWD. on the ChemTrails Flu; NSA. Thanks, this is verbatum from that of the MIKE BLAIR Report, info. This is what I settled on as far as the low altitude spraying. There has been a calling, if you will, for me to get into the air, for the retrieval of samples and analyses from ChemTrails Watchers and Groups all over. All we need is the funding via donations. We have set up a p.O. Box to receive this. Paying for Jet, Crew of call and Sample Analyses. The ChemTrails Groups are going to plan the "Reporting Points" from a large area of the US so we can get the Dispatch for retrieval. Pass the word on if you like. Mike Castle P.O. Box 1161 Richmond, IN. 47375-1161 Apparently many are looking for somebody to do something and I guess they have decided I'm Qualified and let's get something done about acquiring Analytical evidence of the ChemTrails Phenomena before they stop spraying. A very large portion of the populace has been afflicted, as you know, with this mystery illness. Comments.... Best Regards Mike Castle --- Dave <[EMAIL PROTECTED] wrote: forwarded... Dave Hartley http://www.Asheville-Computer.com/dave -----Original Message----- From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED]]On Behalf Of Dan Sewell Ward Sent: Saturday, January 22, 2000 2:48 PM To: [EMAIL PROTECTED] Subject: [ncnculture] Chemtrails Flu National Security Agency (NSA)... Warfare Chemicals being Tested: The strange-looking streaks in the sky aren't your imagination. They are anti-bacteriological warfare chemicals being tested by the federal government. And the public has been kept in the dark. The chemical spraying to the "unconventional pathogen countermeasures program" of the top secret Defense Advanced Research Projects Agency (DARPA). NOTES : (1) Novavax is a bio pharmaceuticals company. (2) BCTP is made of water, soybean oil, Triton X 100 detergent and the solvent tri-n-butyl phosphate. BCTP envelops VIRUSES and SPORES, causing them to explode and thus destroying them upon contact. (3) BCTP's research studies were funded by the Defense Advanced Research Projects Agency (DARPA). BCTP appears to inactivate the virus on contact." The research is funded by DARPA's "Unconventional Pathogen Countermeasures Program" [GO TO : http://www.darpa.mil/DSO/rd/UPC/index.html ]. The U-M and Novavax have filed a patent application covering BCTP's use as a decontamination agent forvarious anti-microbial applications. **************************************************************** Advanced Biological and Medical Technologies: Biological Warfare Defense Unconventional Pathogen Countermeasures The goal of the Unconventional Pathogen Countermeasures program is to develop and demonstrate defensive technologies that afford the greatest protection to uniformed warfighters, and the defense personnel who support them, during U.S. military operations. While no defense may stop a determined adversary from unleashing biological weapon, a sufficiently robust array of pathogen defenses and countermeasures — deterrents in their own right — will reduce the probable damage that would result from biological weapons used in a particular operation. The most sinister offensive biological warfare scenario employs surprise, immediate proximity, and rapidly lethal, persistent agents in overwhelming quantities. Under these circumstances, real-time sensing, donning of physical protection, and conventional nonmedical countermeasures are only marginally effective. An effective operational defense ideally requires instantly available or emplaced countermeasures that can defeat biological threats as they enter the body and before they reach and attack target cells and tissues. The focus of the Unconventional Pathogen Countermeasures program is the development of revolutionary, broad-spectrum, medical countermeasures against significantly pathogenic microorganisms and/or their pathogenic products. These countermeasures will be versatile enough to eliminate biological threats, whether from natural sources or modified through bioengineering or other manipulation. They will also have the potential to provide protection both within the body and at the most common portals of entry (e.g., inhalation, ingestion, transcutaneous). Strategies include but are not limited to: (1) Defeat of a pathogen's ability to enter the body, traverse the bloodstream or lymphatics, and enter target tissues. (2) Identification of novel pathogen vulnerabilities based on fundamental, critical molecular mechanisms of survival or pathogenesis (e.g., Type III secretion, cellular energetics, virulence modulation). (3) Construction of unique, robust vehicles for the delivery of countermeasures into or within the body. (4) Modulation of the advantageous and/or deleterious aspects of the immune response to significantly pathogenic microorganisms and/or their pathogenic products in the body. <A HREF="http://www.ctrl.org/">www.ctrl.org</A> DECLARATION & DISCLAIMER ========== CTRL is a discussion & informational exchange list. Proselytizing propagandic screeds are not allowed. Substance—not soap-boxing! These are sordid matters and 'conspiracy theory'—with its many half-truths, misdirections and outright frauds—is used politically by different groups with major and minor effects spread throughout the spectrum of time and thought. That being said, CTRL gives no endorsement to the validity of posts, and always suggests to readers; be wary of what you read. CTRL gives no credence to Holocaust denial and nazi's need not apply. Let us please be civil and as always, Caveat Lector. ======================================================================== Archives Available at: http://home.ease.lsoft.com/archives/CTRL.html http:[EMAIL PROTECTED]/ ======================================================================== To subscribe to Conspiracy Theory Research List[CTRL] send email: SUBSCRIBE CTRL [to:] [EMAIL PROTECTED] To UNsubscribe to Conspiracy Theory Research List[CTRL] send email: SIGNOFF CTRL [to:] [EMAIL PROTECTED] Om
